journal article·2022-11-04Open access

Biological Monitoring via Urine Samples to Assess Healthcare Workers’ Exposure to Hazardous Drugs: A Scoping Review

Chun-Yip Hon, Naqiyah Motiwala

Applied Sciences· Volume 12· Issue 21

Abstract

Although biological monitoring is beneficial as it assesses all possible routes of exposure, urine sampling of healthcare workers exposed to hazardous drugs is currently not routine. Therefore, a scoping review was performed on this subject matter to understand what is known about exposure and identify knowledge gaps. A literature search was performed on three databases: ProQuest, Web of Science, and PubMed. Articles published between 2005 and 2020 and written in English were included. Overall, this review consisted of 39 full-text articles. The studies varied with respect to design, sample sizes, sample collection times, and drugs examined. Many articles found at least one sample had detectable levels of a hazardous drug. Studies reported urinary drug contamination despite controls being employed. Knowledge gaps included a lack of an exposure limit, lack of a standardized sampling method, and lack of correlation between health effects and urinary contamination levels. Due to differences in sample collection and analysis, a comparison between studies was not possible. Nevertheless, it appears that biological monitoring via urine sampling is meaningful to aid in understanding healthcare workers’ exposure to hazardous drugs. This is supported by the fact that most studies reported positive urine samples and that case-control studies had statistically significant findings.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Safe Handling of Antineoplastic Drugs · Pharmaceutical studies and practices · Biosimilars and Bioanalytical Methods

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Occupational and Public Health, Toronto Metropolitan University, Toronto, ON M5B 2K3, Canada

Funding

BioTalent Canada

References (64)

Show source-provided references
1. Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings10.3322/canjclin.56.6.354 ↗
2. Antineoplastic drug exposure in an ambulatory setting: A pilot study10.1097/NCC.0000000000000143 ↗
3. Handling anticancer drugs: From hazard identification to risk management?10.1196/annals.1371.008 ↗
4. Occupational Exposure to Antineoplastic Agents10.1177/2165079916662660 ↗
5. Occupational exposure to antineoplastic drugs: Identification of job categories potentially exposed throughout the hospital medication system10.5491/SHAW.2011.2.3.273 ↗
6. Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs10.1016/j.mrrev.2017.08.002 ↗
7. Biomonitoring of pharmacists and nurses at occupational risk from handling antineoplastic agents10.1111/ijpp.12590 ↗
8. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings a review of the evidence10.1097/JOM.0000000000000249 ↗
9. An investigation of oxidative dna damage in pharmacy technicians exposed to antineoplastic drugs in two Chinese hospitals using the urinary 8-OHdG assay
10. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers10.1097/JOM.0b013e3181f72b63 ↗
11. An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers10.1016/j.jchromb.2010.04.030 ↗
12. Biological monitoring of exposure: Trends and key developments10.1539/joh.47.22 ↗
13. WHO (2015). Human Biomonitoring: Facts and Figures, WHO. Available online: http://www.euro.who.int/__data/assets/pdf_file/0020/276311/Human-biomonitoring-facts-figures-en.pdf.
14. Biomonitoring of occupational exposure to 5-FU by assaying α-fluoro-β-alanine in urine with a highly sensitive UHPLC-MS/MS method10.1039/C8AN00479J ↗
15. A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers10.1016/j.jchromb.2017.06.028 ↗
16. (2011, November 30). CDC-NIOSH Publications and Products—Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings (2004-165), Available online: http://www.cdc.gov/niosh/docs/2004-165/.
17. Antineoplastic drug contamination on the hands of employees working troughout the hospital medication system
18. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities10.1007/s00420-004-0595-1 ↗
19. Munn, Z., Peters, M.D.J., Stern, C., Tufanaru, C., McArthur, A., and Aromataris, E. (2018). Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol., 18.10.1186/s12874-018-0611-x ↗
20. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation10.7326/M18-0850 ↗
21. Updated methodological guidance for the conduct of scoping reviews10.11124/JBIES-20-00167 ↗
22. Verification of surface contamination of Japanese cyclophosphamide vials and an example of exposure by handling10.1177/1078155211419543 ↗
23. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees10.1016/j.mrgentox.2005.07.008 ↗
24. Exposure to antineoplastic drugs in two UK hospital pharmacy units
25. Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs10.1007/s00420-006-0111-x ↗
26. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses
27. Genotoxicity assessment in oncology nurses handling antineoplastic drugs10.1093/mutage/gem032 ↗
28. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital10.1007/s00420-007-0284-y ↗
29. An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese community hospital designated for the treatment of cancer10.1248/jhs.55.750 ↗
30. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment
31. Evaluation of environmental contaminations and occupational exposures involved in preparation of chemotherapeutic drugs10.1248/yakushi.130.903 ↗
32. Biological monitoring of occupational exposure to 5-fluorouracil: Urinary α-fluoro-β-alanine assay by high performance liquid chromatography tandem mass spectrometry in health care personnel10.1016/j.jchromb.2010.02.011 ↗
33. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan10.1177/1078155210380485 ↗
34. Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure10.1002/jso.21740 ↗
35. Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan10.1177/1078155210369851 ↗
36. Risks to health professionals from hazardous drugs in Japan: A pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide10.1177/1078155209358632 ↗
37. Occupational exposure to antineoplastic drugs in seven Italian hospitals: The effect of quality assurance and adherence to guidelines10.1177/1078155210381931 ↗
38. Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs10.1093/mutage/geq102 ↗
39. Occupational exposure to antineoplastic drugs in four Italian health care settings10.1016/j.toxlet.2011.03.028 ↗
40. Environmental and biological monitoring of platinum-containing drugs in two hospital pharmacies using positive air pressure isolators
41. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital10.1186/2193-1801-2-273 ↗
42. Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital
43. Occupational exposure to cyclophosphamide in nurses at a single center10.1097/JOM.0000000000000097 ↗
44. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation10.1177/1078155214522840 ↗
45. Antineoplastic drug contamination in the urine of Canadian healthcare workers10.1007/s00420-015-1026-1 ↗
46. Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: A multicentric approach10.1007/s00420-014-0993-y ↗
47. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC)10.2486/indhealth.2014-0025 ↗
48. A multicenter study of biological effects assessment of pharmacy workers occupationally exposed to antineoplastic drugs in Pharmacy Intravenous Admixture Services10.1016/j.jhazmat.2016.04.008 ↗
49. Pilot study of biological monitoring of four antineoplastic drugs among Canadian healthcare workers10.1177/1078155216643860 ↗
50. Biological monitoring of healthcare workers exposed to antineoplastic drugs: Urinary assessment of cyclophosphamide and ifosfamide
51. Environmental and biological monitoring on an oncology ward during a complete working week10.1016/j.toxlet.2018.05.002 ↗
52. Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination10.1016/j.toxlet.2018.05.031 ↗
53. Biological monitoring of the oncology healthcare staff exposed to cyclophosphamide in two hospitals in Tehran
54. Antineoplastic drug occupational exposure: A new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker10.1016/j.toxlet.2019.08.022 ↗
55. Quantification of healthcare workers’ exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study10.1177/1078155220907129 ↗
56. Occupational exposure to cytostatic/antineoplastic drugs and cytogenetic damage measured using the lymphocyte cytokinesis-block micronucleus assay: A systematic review of the literature and meta-analysis10.1016/j.mrrev.2016.05.001 ↗
57. A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs10.1080/15459624.2016.1237026 ↗
58. Variability of urinary concentrations of bisphenol A in spot samples, first morning voids, and 24-hour collections10.1289/ehp.1002701 ↗
59. Clinical pharmacokinetics of cyclophosphamide10.2165/00003088-200544110-00003 ↗
60. Analytical strategies for assessing occupational exposure to antineoplastic drugs in healthcare workplaces
61. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals10.1177/1078155216676632 ↗
62. A summary of the ’ALARP’ principle and associated thinking10.1080/00223131.2018.1551814 ↗
63. Antineoplastic Drug Contamination of Surfaces Throughout the Hospital Medication System in Canadian Hospitals10.1080/15459624.2013.789743 ↗
64. Cancer Care Ontario (2018). A Quality Initiative of the Safe Handling of Cytotoxics, Cancer Care Ontario.